The Ritlecitinib Pregnancy Registry

What is a registry and why is it important?

A pregnancy registry is a study that collects health information from women who use prescription medicines or vaccines when they are pregnant. Information is also collected on the newborn baby.

Who is eligible to participate?

Patients may be eligible if they:

  • Are currently pregnant or have been pregnant within the past year
  • Are a resident of the United States
  • Have been diagnosed with alopecia areata by a healthcare provider

How do I enroll a patient?

If you have patients who you think may be eligible, you can help them enroll by having them:

Consent to contact

Complete the consent to contact card here and a registry team member will contact them

Email the registry team:

Call the registry team

Call the registry team toll-free at
1-877-390-2940 (hours of operation 8.30am – 5.00 pm EST Monday-Friday)

Why is this study needed?

Since pregnant patients are not typically allowed to enroll into clinical trials, there is limited data on the safety of ritlecitinib when used during pregnancy.

More information is needed to understand the potential risks of exposure during pregnancy.

Eligible patients and their healthcare providers will provide information to the registry about their pregnancies and the health of their infants up to 1 year of age. This information can be provided by completing paper forms, via the free registry app, via the website portal or via a short phone interview with one of the registry team members. Only information normally documented in patients’ medical records will be collected.

There will be:

  • No extra doctors’ visits or additional testing
  • No changes to patients’ medications or care

Eligible patients and their healthcare providers will receive compensation for providing data to the registry.

As the pregnant woman’s healthcare provider(s) you will be asked to provide data at enrollment, approximately the end of the second trimester, and at the end of pregnancy. For live-born infants, healthcare provider(s) will be asked to provide data at approximately 4 and 12 months after delivery.

The following data will be collected:

  • Maternal obstetrical history
  • Family history of congenital malformations
  • Baseline and ongoing pregnancy information, including pregnancy dating and prenatal test information
  • Maternal exposures during pregnancy
  • Maternal medical conditions and pregnancy complications
  • Pregnancy outcome information, including fetus/infant characteristics and presence of congenital malformations
  • Infant growth and development information

Healthcare providers will be compensated when they submit data to the registry.

Eligible patients will be asked to provide information to the registry at enrollment, including basic demographic information (e.g., race, ethnicity, education), height and weight and information about their history of alopecia areata including treatment.

Thank you for your support in recruiting potential participants.

Register